Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
Holding PDSB?
Track your performance easily
PDSB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.53 - $6.68
Previous Close$2.1
Volume582.25K
Average Volume (3M)383.40K
Market Cap
$78.37M
Enterprise Value$53.24M
Total Cash (Recent Filing)$49.80M
Total Debt (Recent Filing)$24.67M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 27, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding37,409,137
10 Day Avg. Volume758,007
30 Day Avg. Volume383,402
Standard Deviation0.33
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.43
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$15.67Price Target Upside673.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
PDS Biotechnology News
PremiumCompany Announcements
PDS Biotechnology Highlights Clinical Progress and Q3 Results
PremiumCompany Announcements
PDS Biotechnology’s Versamune® HPV Shows Promise in Phase 2 Trial
Bulls Say, Bears Say
Bulls Say
Clinical AdvancesVersamune HPV, with and without Keytruda, is uniquely becoming the dominant force in HPV-related cancers.
Innovative TherapiesPDS01ADC and enzalutamide could be a potent therapeutic one-two punch in prostate cancer.
Strategic DevelopmentsAlterations to VERSATILE-003, if approved by the FDA, would allow the company to preserve critical capital and resources while establishing new protocols to report results in an expedited manner.
Bears Say
Data ConcernsPDS shares tumbled following the company's 3Q24 update, potentially driven by recent discussions around KEYNOTE-689 data.
Market Entry DelayThere is a potential 1+ year delay to the market entry of the triplet therapy, affecting the price target.
Prognosis VariablesHPV-positive status and low PDL1 expression remain key variables associated with poor prognosis against current standard of care, which isn't fully appreciated by the market.
---
Ownership Overview
1.52%
Insiders
5.20% Mutual Funds
2.16% Other Institutional Investors
86.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $1.53 and its highest was $6.68 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
Currently, no data Available
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Mar 27, 2025 which is in 126 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Nov 14, 2024. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.007.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -$0.31.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 37,409,138 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went down -18.478%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Among the largest hedge funds holding PDS Biotechnology Corporation’s share is New Leaf Venture Partners, L.L.C.. It holds PDS Biotechnology Corporation’s shares valued at N/A.
---
PDS Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (673.83% Upside)
$15.67 (673.83% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.69%
12-Months-Change
Fundamentals
Return on Equity
-174.49%
Trailing 12-Months
Asset Growth
-8.28%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
---
PDSB Earnings Call
Q3 2024
0:00 / 0:00
---
PDSB Stock 12 Month Forecast
Average Price Target
$15.67
▲(673.83% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Oncternal Therapeutics
―
TRACON Pharmaceuticals
―
Molecular Templates
―
Best Analysts Covering PDSB
1 Year
1 Year Success Rate
4/25 ratings generated profit
1 Year Average Return
-25.19%
reiterated a buy rating 6 days ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 16.00% of your transactions generating a profit, with an average return of -25.19% per trade.
---